Research Advances on Organelle-Targeted Drug Delivery Systems for the Treatment of Brain Tumors and Central Nervous System Inflammation
Open Access
- 10 September 2026
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1140
Abstract
Central nervous system (CNS) inflammation and brain tumor treatment are constrained by the heterogeneity of the blood–brain barrier (BBB) and blood–brain tumor barrier (BBTB), as well as by the sequential barriers to drug delivery across lesions, target cells and subcellular organelles. Simply increasing brain exposure does not ensure that drugs reach their actual sites of action. This review systematically examines the pathological roles and therapeutic rationales of mitochondrial, lysosomal, nuclear, endoplasmic reticulum and Golgi apparatus dysfunction in neuroinflammation and glioblastoma within a two-stage delivery framework encompassing barrier crossing, lesion accumulation, cellular uptake and subcellular organelle localization. It also summarizes key design considerations for liposomes, polymeric nanoparticles, biomimetic membrane-based carriers, exosome-like carriers and focused ultrasound-assisted delivery strategies. Furthermore, translational bottlenecks are discussed, including BBB/BBTB heterogeneity, endosomal/lysosomal escape, organelle off-targeting, long-term safety and the extrapolation of preclinical models. Finally, personalized delivery designs guided by cascade targeting, dynamic visualization-based validation and disease stratification are proposed to support precise treatment of CNS inflammation and brain tumors.Keywords
Funding Information
- CAMS innovation Fund for Medical Science (2021-I2M-1-026)
This publication has 157 references indexed in Scilit:
- Blood‐Brain Barrier‐Penetrating Nanocarriers Enable Microglial‐Specific Drug Delivery in Hypothalamic NeuroinflammationAdvanced Healthcare Materials, 2025
- Organelle‐Targeting NanoparticlesAdvanced Science, 2025
- Lysosome‐Targeting Protein Degradation Through Endocytosis Pathway Triggered by Polyvalent Nano‐Chimera for AD TherapyAdvanced Materials, 2024
- Dopamine‐conjugated extracellular vesicles induce autophagy in Parkinson's diseaseJournal of Extracellular Vesicles, 2024
- Inhibiting Mitochondrial Damage for Efficient Treatment of Cerebral Ischemia‐Reperfusion Injury Through Sequential Targeting Nanomedicine of Neuronal Mitochondria in Affected Brain TissueAdvanced Materials, 2024
- Endoplasmic reticulum stress in diseasesMedcomm, 2024
- Lipid‐Polymer Nanoparticles Mediate Compartmentalized Delivery of Cas9 and sgRNA for Glioblastoma Vasculature and Immune ReprogrammingAdvanced Science, 2024
- Ameliorating Mitochondrial Dysfunction of Neurons by Biomimetic Targeting Nanoparticles Mediated Mitochondrial Biogenesis to Boost the Therapy of Parkinson's DiseaseAdvanced Science, 2023
- Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiformeBioengineering & Translational Medicine, 2023
- Specific anti‐glioma targeted‐delivery strategy of engineered small extracellular vesicles dual‐functionalised by Angiopep‐2 and TAT peptidesJournal of Extracellular Vesicles, 2022